Merck plans to present the results at a medical meeting, then share the data with regulators.
No new safety signals were identified.
Phase 3 trial met primary endpoint
Merck reported Phase 3 KEYNOTE-C93 met its primary endpoint, with Keytruda monotherapy improving progression-free survival versus carboplatin-paclitaxel in dMMR advanced or recurrent endometrial cancer.
Interim overall survival analysis showed a favorable trend for Keytruda, though data were not mature; the trial continues with a future OS readout planned.
The trial enrolled 299 patients; Keytruda was dosed at 400 mg every six weeks for up to 18 cycles versus six cycles of platinum-doublet chemotherapy.
MRK•
